

Catalog# BP-50549

Briakinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody

Briakinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralizes interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. Briakinumab Biosimilar uses the same protein sequences as the therapeutic antibody briakinumab.

Product Details	
CAS No.	339308-60-0
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Briakinumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human interleukin-12 (IL-12) and interleukin-23 (IL-23)
Purity	>95%
Molecular Weight	143.86 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered PBS solution, pH 7.4
Storage conditions	4°C for short time, -20°C or -80°C for long time.